Literature DB >> 21744472

External-beam radiotherapy for pediatric and young adult desmoid tumors.

Michael S Rutenberg1, Daniel J Indelicato, Jacquelyn A Knapik, Joanne P Lagmay, Christopher Morris, Robert A Zlotecki, Mark T Scarborough, Charles P Gibbs, Robert B Marcus.   

Abstract

BACKGROUND: To report long-term outcomes following radiotherapy for desmoid tumors in children and young adults and identify variables impacting local-regional control and treatment complications. PROCEDURE: From 1978 to 2008, 30 patients <30 years old were treated with radiotherapy for a pathologically confirmed desmoid tumor. The median age at radiotherapy was 23.7 years old (range, 10.3-29.9). Fifteen patients underwent definitive radiotherapy, 14 received radiotherapy after gross total resection, and 1 received preoperative radiotherapy. Sixteen patients received 1.8 Gy once daily and 14 received 1.2 Gy twice daily. Variables analyzed for prognostic value included gender, age at diagnosis, primary or recurrent presentation, age at radiotherapy, tumor site, tumor size, extent of resection, fractionation schedule, and radiotherapy dose.
RESULTS: The actuarial 15-year overall survival and local-regional control rates were 96% and 55%, respectively. Local-regional control in patients <18 years old at the time of radiotherapy was 20% versus 63% in those 18-30 years old (P = 0.08). Local-regional control rates for tumors receiving ≥ 55 Gy and < 55 Gy were 79% and 30%, respectively (P = 0.02). No other factors had a statistically significant association with local-regional control by univariate analysis. Twelve of 30 patients experienced grade 3-4 complications, including pathologic fractures, impaired range of motion, pain, and in-field skin cancers.
CONCLUSIONS: The role of radiotherapy in managing young patients with desmoid tumors remains unclear. Younger patient age is associated with inferior local-regional control following RT. In children and young adults, doses ≥55 Gy were associated with improved tumor control, but also lead to increased risk of complications.
Copyright © 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2010        PMID: 21744472     DOI: 10.1002/pbc.22916

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  18 in total

1.  Electrochemotherapy for the treatment of recurring aponeurotic fibromatosis in a dog.

Authors:  Enrico P Spugnini; Giovanni Di Tosto; Scirin Salemme; Luca Pecchia; Maurizio Fanciulli; Alfonso Baldi
Journal:  Can Vet J       Date:  2013-06       Impact factor: 1.008

2.  The Role of Radiotherapy in the Treatment of Primary or Recurrent Desmoid Tumors and Long-Term Results.

Authors:  Şefika Arzu Ergen; Elif Eda Tiken; Didem Çolpan Öksüz; Fazilet Öner Dinçbaş; Sergülen Dervişoğlu; Nil Molinas Mandel; Murat Hız; Sedat Koca
Journal:  Balkan Med J       Date:  2016-05-01       Impact factor: 2.021

Review 3.  A systematic review of active treatment options in patients with desmoid tumours.

Authors:  X Yao; T Corbett; A A Gupta; R A Kandel; S Verma; J Werier; M Ghert
Journal:  Curr Oncol       Date:  2014-08       Impact factor: 3.677

4.  Treatment and follow-up strategies in desmoid tumours: a practice guideline.

Authors:  M Ghert; X Yao; T Corbett; A A Gupta; R A Kandel; S Verma; J Werier
Journal:  Curr Oncol       Date:  2014-08       Impact factor: 3.677

5.  Magnetic resonance-guided focused ultrasound treatment of extra-abdominal desmoid tumors: a retrospective multicenter study.

Authors:  Alberto Bazzocchi; Matthew Bucknor; Pejman Ghanouni; Andrew Dobrotwir; Rachelle Bitton; Jarrett Rosenberg; Kristen Telischak; Maurizio Busacca; Stefano Ferrari; Ugo Albisinni; Shannon Walters; Garry Gold; Kristen Ganjoo; Alessandro Napoli; Kim Butts Pauly; Raffi Avedian
Journal:  Eur Radiol       Date:  2016-05-05       Impact factor: 5.315

6.  Desmoid: the role of local therapy in an era of systemic options.

Authors:  Brian E Walczak; Peter S Rose
Journal:  Curr Treat Options Oncol       Date:  2013-09

7.  Efficacy of vinorelbine combined with low-dose methotrexate for treatment of inoperable desmoid tumor and prognostic factor analysis.

Authors:  Shu Li; Zhengfu Fan; Zhiwei Fang; Jiayong Liu; Chujie Bai; Ruifeng Xue; Lu Zhang; Tian Gao
Journal:  Chin J Cancer Res       Date:  2017-10       Impact factor: 5.087

Review 8.  The Role of Radiation Therapy for Symptomatic Desmoid Tumors.

Authors:  Wen Shen Looi; Daniel J Indelicato; Michael S Rutenberg
Journal:  Curr Treat Options Oncol       Date:  2021-03-01

Review 9.  Rationale for the use of tyrosine kinase inhibitors in the treatment of paediatric desmoid-type fibromatosis.

Authors:  Monika Sparber-Sauer; Daniel Orbach; Fariba Navid; Simone Hettmer; Stephen Skapek; Nadège Corradini; Michela Casanova; Aaron Weiss; Matthias Schwab; Andrea Ferrari
Journal:  Br J Cancer       Date:  2021-03-15       Impact factor: 7.640

10.  Desmoid fibromatosis in pediatric patients: management based on a retrospective analysis of 59 patients and a review of the literature.

Authors:  Caroline Oudot; Daniel Orbach; Véronique Minard-Colin; Jean Michon; Pierre Mary; Christophe Glorion; Sylvie Helfre; Jean-Louis Habrand; Odile Oberlin
Journal:  Sarcoma       Date:  2012-08-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.